Thursday, April 30, 2026 4:05:31 PM
Bullish
Recent ASBP News
- Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio • ACCESS Newswire • 05/07/2026 03:00:00 PM
- Aspire Biopharma Announces $5.0 Million Share Repurchase Program • ACCESS Newswire • 04/27/2026 12:30:00 PM
- Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition • ACCESS Newswire • 04/20/2026 12:30:00 PM
- Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo • ACCESS Newswire • 04/17/2026 12:00:00 PM
- Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue • ACCESS Newswire • 04/16/2026 12:30:00 PM
- Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion • ACCESS Newswire • 04/15/2026 12:00:00 PM
- Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion • ACCESS Newswire • 03/19/2026 12:00:00 PM
- Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director • ACCESS Newswire • 03/17/2026 12:30:00 PM
- Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026 • ACCESS Newswire • 03/12/2026 12:00:00 PM
- Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack • ACCESS Newswire • 03/10/2026 12:30:00 PM
- Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship • ACCESS Newswire • 02/25/2026 01:30:00 PM
- Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements • ACCESS Newswire • 02/20/2026 01:00:00 PM
- Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record • ACCESS Newswire • 02/19/2026 01:00:00 PM
- Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R)) • ACCESS Newswire • 02/17/2026 01:30:00 PM
- Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors • ACCESS Newswire • 02/13/2026 01:00:00 PM
- Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R)) • ACCESS Newswire • 02/12/2026 01:00:00 PM
- Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements • ACCESS Newswire • 02/11/2026 12:45:00 PM
- Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement • ACCESS Newswire • 02/10/2026 01:00:00 PM
- Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit • ACCESS Newswire • 02/05/2026 01:00:00 PM
- Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution • ACCESS Newswire • 02/03/2026 01:00:00 PM
- Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin • ACCESS Newswire • 01/29/2026 01:00:00 PM
- Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks • ACCESS Newswire • 01/27/2026 01:00:00 PM
- Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity • ACCESS Newswire • 01/22/2026 01:00:00 PM
- Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign • ACCESS Newswire • 01/21/2026 01:00:00 PM
- Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief • ACCESS Newswire • 01/20/2026 01:00:00 PM

